Summary
The supplied FDA label excerpts are about suicidal thoughts/behaviors risk (boxed warning and Section 5.1), but the AI-generated content claims are almost entirely about pricing, insurance coverage, generic availability, formulation differences, bioequivalence, and unrelated patent/ingredient assertions. These are not supported or contradicted by the provided label sections and therefore cannot be evaluated as on-label for the requested suicidality topic.
Category Scores
Accurate Statements
Unsupported Statements
The price of generic fluoxetine can vary depending on the specific dosage, the number of pills in a prescription, and the pharmacy where it is purchased.
Not addressed in the provided FDA label excerpts (only suicidality boxed warning/Section 5.1 were supplied).
Generic medications are typically less expensive than their brand-name counterparts.
Not addressed in the provided FDA label excerpts.
Generic fluoxetine is generally available at a significantly lower cost than brand-name Prozac.
Not addressed in the provided FDA label excerpts.
A prescription for 30 capsules of 20 mg generic fluoxetine might range from approximately $10 to $40 depending on the pharmacy and insurance coverage.
Not addressed in the provided FDA label excerpts.
The cost of generic fluoxetine can be lower with discount cards or programs.
Not addressed in the provided FDA label excerpts.
The cost of generic fluoxetine can differ between pharmacies.
Not addressed in the provided FDA label excerpts.
Comparing prices at various retail pharmacies and online pharmacies can help identify the most affordable option.
Not addressed in the provided FDA label excerpts.
Many pharmacies offer online price comparison tools or allow checking prices via their websites or apps.
Not addressed in the provided FDA label excerpts.
Patient assistance programs or discount cards may further reduce out-of-pocket cost for generic fluoxetine.
Not addressed in the provided FDA label excerpts.
Several elements affect the price of generic fluoxetine, including manufacturing costs.
Not addressed in the provided FDA label excerpts.
The price of generic fluoxetine is affected by the number of generic manufacturers producing the drug.
Not addressed in the provided FDA label excerpts.
The price of generic fluoxetine is affected by competition among generic manufacturers.
Not addressed in the provided FDA label excerpts.
The price of generic fluoxetine is affected by dispensing fees charged by pharmacies.
Not addressed in the provided FDA label excerpts.
The strength and quantity of the medication prescribed play a direct role in the final price of generic fluoxetine.
Not addressed in the provided FDA label excerpts.
The patent for fluoxetine (brand name Prozac) has long since expired.
Not addressed in the provided FDA label excerpts.
Because the patent for fluoxetine has expired, generic versions are available.
Not addressed in the provided FDA label excerpts.
The original patent protection for fluoxetine developed by Eli Lilly and Company ended many years ago, allowing other pharmaceutical companies to manufacture and market generic versions.
Not addressed in the provided FDA label excerpts.
The primary difference between brand-name Prozac and generic fluoxetine is the inactive ingredients used in their formulations.
Not addressed in the provided FDA label excerpts.
The inactive ingredients in Prozac and generic fluoxetine can include fillers and binders.
Not addressed in the provided FDA label excerpts.
The active ingredient fluoxetine hydrochloride is identical in both Prozac and generic fluoxetine.
Not addressed in the provided FDA label excerpts.
The U.S. FDA ensures that generic drugs are bioequivalent to their brand-name counterparts.
Not addressed in the provided FDA label excerpts.
Bioequivalent generic drugs work in the body in the same way as brand-name drugs.
Not addressed in the provided FDA label excerpts.
Bioequivalent generic drugs have the same therapeutic effect as brand-name drugs.
Not addressed in the provided FDA label excerpts.
Insurance plans typically cover generic medications, including fluoxetine.
Not addressed in the provided FDA label excerpts.
Insurance plans typically provide a lower co-payment for generic medications than for brand-name drugs.
Not addressed in the provided FDA label excerpts.
The exact co-payment amount depends on the specific insurance plan's formulary and the pharmacy's agreement with the insurer.
Not addressed in the provided FDA label excerpts.
Patients should check with their insurance provider or pharmacy regarding coverage details.
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
No actual labeling-required suicidality guidance is present in the listed AI claims (e.g., monitoring for worsening/suicidality during initial treatment or around dose changes; family/caregiver observation; boxed warning age range details).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Because the provided AI claims are mainly about pricing/availability and do not contain specific FDA-label safety instructions or treatment risks, there is no direct label-based safety misstatement in the supplied text. However, omission of the required boxed warning/monitoring content makes the overall answer insufficient for the purported suicidality-topic alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the supplied FDA label excerpts (which only cover suicidality risk). The response does not include on-label suicidality monitoring/warning details required for the topic.
Suggested Improvement
Limit the response to the boxed warning and Section 5.1 content provided (increased suicidality risk in ages 18–24 in short-term studies; no increased risk beyond age 24 and reduction in ≥65; close monitoring especially during initial months and around dose changes; advise families/caregivers on observation and prompt reporting; include the boxed-warning age limitation language).